Epidemiological, molecular and genetic studies have indicated that high serum vitamin D levels are associated with lower risk of several autoimmune diseases. The vitamin D receptor (VDR) binding sites in monocytes and dendritic cells (DCs) are more common in risk genes for diseases with latitude dependence than in risk genes for other diseases. The transcription factor genes Zinc finger MIZ domain-containing protein 1 (ZMIZ1) and interferon regulatory factor 8 (IRF8)-risk genes for many of these diseases-have VDR binding peaks co-incident with the risk single nucleotide polymorphisms (SNPs). We show these genes are responsive to vitamin D: ZMIZ1 expression increased and IRF8 expression decreased, and this response was affected by genotype in different cell subsets. The IL10/IL12 ratio in tolerogenic DCs increased with vitamin D. These data indicate that vitamin D regulation of ZMIZ1 and IRF8 in DCs and monocytes contribute to latitude-dependent autoimmune disease risk.
Introduction
Many of the most common autoimmune diseases show a latitude-dependent prevalence, independent of ethnic differences, pointing to the importance of sun exposure, and so, at least in part, vitamin D production, in pathogenesis. These latitude-dependent autoimmune diseases (LDADs) include multiple sclerosis (MS), Type 1 diabetes, rheumatoid arthritis, Crohn's disease, systemic lupus erythematosus and psoriasis (1) . The effect can be very strong, for example in Australia, MS is >7 × more common in Tasmania than Northern Queensland, suggesting six in seven people who develop MS in Tasmania would not develop MS had they grown up in the northern latitude (2) . Ultraviolet light, and its product vitamin D, have been shown to clinically improve autoimmune diseases in some studies, but not others (3) . Given the complexity of the vitamin D regulatory network (4) , different approaches to supplementation, and individual variation in immune states and response, this is not surprising. Further, the mechanism conferring protection with latitude and/or vitamin D supplementation has not been established. The recent and expanding understanding of the importance of vitamin D in immune tolerance (5) , the role of vitamin D deficiency in MS risk (6) and the over-representation of genes that control vitamin D metabolism and effect, as part of the genetic architecture of LDADs (7), establish vitamin D-influenced immune pathways as important targets for translational research. More effective utilization of the vitamin D pathway in protection from autoimmunity will require a higher definition of the critical pathogenic pathways and the immune cell subsets through which they act. This definition might be improved by investigating the effect of common genetic variation of vitamin D affected genes on vitamin D function using the recent findings from genome wide association studies (GWAS) of LDADs.
Autoimmune disorders result from the interaction of complex genetic predisposition with environmental factors. For many disorders much of the heritability has now been explained by GWAS (8) (9) (10) . Identified genes affecting pathogenesis include the vitamin D regulating genes CYP24A1 and CYP27B1 (9) ; in addition, many of the other risk genes are regulated by the vitamin D receptor (VDR) (7, 11) . The VDR, when bound to active vitamin D (1,25D3), is a transcription factor that regulates many genes, subject to interaction with other transcription factors, dependent on cell type and differentiation state, affected by methylation and other environmental factors (12, 13) .
Given these complex interactions, the current clinical management of many vitamin D affected autoimmune diseases, based on adjusting serum vitamin D3 precursor (25D3) levels to a certain range using oral supplementation with 25D3, may be ineffective (12) . This strategy assumes the target effect, inducing tolerance in immune cells, can be achieved from systemic dosing with the inactive precursor. The immune cells, which need to be modulated to reduce autoimmune activity, may be more responsive to 1,25D3 or analogues, delivered directly to the target tissue, for example, the cervical lymph node. Serum 25D3 levels have been shown to have low correlation with serum 1,25D3 (14) . Response may depend on immune cell state or other concurrent therapies, and the target immune cell location may be insensitive to changes in serum levels of 25D3. Systemic and local feedback mechanisms, particularly on the VitD pathway itself, may nullify effects of supplementation. To make the best use of vitamin D its regulation in autoimmunity needs to be better understood.
The autoimmune disease risk genes CYP27B1 and CYP24A1 encode the enzymes required for the activation and subsequent breakdown of 1,25D3 and are most highly expressed in mononuclear phagocytic (MP) cells, especially dendritic cells (DCs), in the immune cells examined (15, 16) . Their expression is affected by their risk genotypes. Vitamin D function in DCs therefore likely affects disease pathogenesis, with higher activation and less inactivation being protective. Further, cistromic studies indicate diseases affected by latitude have the highest representation of risk genes amongst the genes near VDR binding peaks (7) . These genes include Zinc finger MIZ domain-containing protein 1 (ZMIZ1), a gene in cis on the antisense strand named ZMIZ1-AS1, and interferon regulatory factor 8 (IRF8)-all highly expressed in MP cells. ZMIZ1 is a risk factor for at least eleven autoimmune conditions, all latitudedependent. It is underexpressed in MS (17, 18) . Its expression is increased by incubation of MP cells with 1,25D3 (18) , and it is most highly expressed in monocytes. Antisense ZMIZ1 (ZMIZ1-AS1) is most highly expressed in differentiated monocytes. A VDR peak is located between the two genes. ZMIZ1 is a transcription factor whose targets have been identified in T cells (19) , but not yet in MP cells. Higher expression in monocytes may be protective, preventing their differentiation into an inflammatory state (18) . IRF8 is a transcription factor more highly expressed in differentiated monocytes, and known to promote their differentiation into inflammatory DCs (iDCs) (20) . Genetic variants of IRF8 are associated with a similar set of LDADS as ZMIZ1, notably MS [19] , systemic lupus erythematosus [20] , rheumatoid arthritis [21] , ulcerative colitis [22] and inflammatory bowel disease [23] . In support of their role in regulating immune states, both genes are associated with blood cell traits (21) .
Since high expression of ZMIZ1 and low expression of IRF8 in MP cells would likely reduce differentiation from monocytes to iDCs and promote a more tolerogenic phenotype, especially in response to vitamin D, we hypothesize such expression of these genes is protective against autoimmunity. If so, the expression will be affected by 1,25D3 in these cells; genotypes increasing the risk of disease will correspond to altered expression; and altered response to vitamin D. In this study we have assessed ZMIZ1, ZMIZ1-AS1 and IRF8 expression in MP cells, cultured with and without 1,25D3. The data supports a role for regulation of these genes in MP cells by vitamin D as contributing to autoimmunity and indicates the transcriptional program controlled by the ZMIZ1/IRF8/VDR axis is a promising target for therapy, especially using vitamin Dbased approaches.
Results

ZMIZ1, ZMIZ1-AS1 and IRF8 have VDR peaks in cis to their genes
The GWAS catalogue contains 32 198 associations between single nucleotide polymorphism (SNP) genotype and disease/trait, 1990 of these associations are for LDADs. LDADs are over-represented in the diseases/traits associated with ZMIZ1 (10 of 33, P < 2e-5) and IRF8 (10 of 39, P < 1e-4). We recently identified VDR binding sites in MP cells using ChIPseq (7) . From these data, two binding sites for VDR can be seen for ZMIZ1/ZMIZ1-AS1 in MP cells, the first is in intron 1 of ZMIZ1 and was detected in monocytes and DCs; the second is in intron 12 of ZMIZ1 and was restricted to monocytes (Fig. 1A) . This second site is next to MS risk SNP rs1250551 (22) . As well as VDR recognition sequences being over-represented at VDR peaks, recognition sequences for the transcription factors SFPI1 and CEBPA/B were very highly over-represented in the MP cells at VDR peaks, suggesting these two TFs interact with the VDR to regulate gene expression. Site 1 has recognition sequences for all three TFs; the site 2 VDR peak does not have a VDR recognition sequence, but has SFPI1 and CEBPA/B recognition sequences. The risk allele is 5.3 kb from the SFPI1 site.
There are three VDR peaks in cis with the IRF8 gene ( Fig. 1B ): the first is 10 KB upstream, and has recognition sequences for VDR, SFPI1 and CEBPA/B, and is used predominantly in iDCs. The second is in intron 5 of IRF8 and is used in all three cell subsets. The third is 55 kb downstream, used only in iDCs, and does not have recognition motifs for the three TFs. MS risk SNP rs13333054 (22) is in the region of the third peak. 
Is risk gene expression pattern consistent among MP cell subsets?
To determine cell subset expression pattern and variation between individuals, we assayed expression of the three risk genes in four MP cell types [monocytes, monocyte-derived immature (undifferentiated) DCs (uDC), iDC and tolerogenic DCs (tDC)] for 32 individuals. All individuals showed the same subset pattern of expression of each gene: ZMIZ1 expression was highest in monocytes and lowest iDCs and tDCs, whereas ZMIZ1-AS1 and IRF8 were highest in iDCs and tDCs, and low, or not detected, in monocytes (Fig. 2 ).
Does risk SNP correspond to gene expression?
We then genotyped the risk SNPs rs1250551 (G/T: ZMIZ1, ZMIZ1-AS1), rs13333054 (C/T: IRF8) for the 32 individuals and compared genotype associations with expression (Fig. 3) . The risk allele (T) corresponded to higher expression of ZMIZ1 in iDCs (P < 0.028), and the protective allele (C) corresponded to higher expression of IRF8 in tDCs (P < 0.039).
Does vitamin D alter expression?
Consistent with the ChIP-seq data, ZMIZ1 expression increased on culture with vitamin D in uDCs (p < 0.0005) and iDCs (p < 0.021). ZMIZ1-AS1 expression was not detected in monocytes, with or without culture with 1,25D3; but expression increased in uDCs (P < 0.00083), iDCs (P < 0.0041) and tDCs (P < 0.0045). IRF8 expression decreased on culture with 1,25D3 tDCs (P < 0.009), and increased in uDCs (P < 0.048) and trended up in monocytes (P < 0.051) (Fig. 4) .
Does genotype affect response to vitamin D?
Risk genotype affected response to vitamin D in tDCs (expression decreased for the protective allele, P < 0.0030, no effect on the risk allele) and monocytes (increase for risk allele, P < .031) for IRF8; ZMIZ1 expression increased for both alleles in uDCs (P = 0.006 and 0.016) and for the protective allele in iDCs (P = 0.017), but with a trend up for each allele in each condition; ZMIZ1-AS1 expression increased for the protective allele only in uDC (P = 0.0079)and iDCs (P = 0.008), the risk allele only in tDC (P = 0.027), but with a trend up for each allele in each condition (Fig. 5) .
Is expression set across all MP cell subsets?
Gene expression levels may be set genetically (for example, by net SNP load) or epigenetically (for example, by methylation), and so remain stable through differentiation. We had previously found that expression of MS risk gene transcription factors ZMIZ1, EOMES and TBX21 were stable over time in blood (18, 23) . We tested if the rank of ZMIZ1, ZMIZ1-AS1 and IRF8 expression was correlated across the four MP cell subsets. ZMIZ1 expression was stable across subsets, but only across the DC subsets: iDC to tDC (r = 0.77, P < 4.75e-6), iDC to uDC (r = 0.71, P < 4.19e-5) and uDC to tDC (r = 0.55, P = 0.003) (Fig. 6A-C) , not between monocytes and DCs. The rank of ZMIZ1 and IRF8 expression was inversely correlated in uDC (r = −0.33, P = 0.07), tDC (r = −0.49, P = 0.0064) and iDCs (r = −0.20, P = 0.2) (Fig. 6D-F ).
Does culture with vitamin D alter DC phenotype through effect on IRF8 and ZMIZ1?
The DC differentiation protocol was based on that of Kalinsky et al. (24) and Rani et al. (25) to model DC functional types found in tissues such as lymph nodes. Since all three genes are affected by vitamin D in tDCs, we tested if their expression altered the IL10/IL12 ratio, as a marker of tolerance state, and if this was correlated to change in expression of the three genes. The ratio was highly increased in tDCs (Fig. 7A) , and more so with vitamin D stimulation, independently of genotype (P < 1.82E-5, Fig. 7C ) and expression level of ZMIZ1-AS1 or IRF8. Increased ZMIZ1 expression was associated with increased IL10/IL12 ratio (r = 0.39, P < 0.036) (Fig. 7B) . The alteration of phenotype by vitamin D is therefore likely to be net of many gene effects, with the ZMIZ1 effect being particularly strong.
Discussion
ZMIZ1, ZMIZ1-AS1 and IRF8 are pan LDAD risk genes which have VDR peaks in cis to their genes in monocytes and DCs, with the risk SNPs in the VDR peak regions. We show here that ZMIZ1, ZMIZ1-AS1 and IRF8 are regulated by vitamin D in these cell types, and that regulation is affected by the risk genotype. Consistent with tolerogenic functions for both ZMIZ1 and vitamin D (5,18), ZMIZ1 is upregulated by vitamin D in uDCs and iDCs. Higher ZMIZ1 expression correlated with higher IL10/IL12 ratio in tDCs. IRF8, known to drive differentiation of iDCs (20) , is downregulated by vitamin D in tDCs, especially for the protective allele. This is consistent with a vitamin D tolerogenic effect of reduced expression of IRF8 in tDCs, inhibiting their differentiation to iDCs. These data provide support for the concept that vitamin D provides protection from the LDADs, at least in part, by controlling the balance of these two transcription factors, with increased expression of ZMIZ1 and decreased expression of IRF8 in MPs retarding development to the inflammatory state (Fig. 8) . Expression of the long non-coding RNA gene ZMIZ1-AS1 was also shown to be affected by vitamin D, and by risk genotype.
The ZMIZ1/ZMIZ1-AS1 protective allele may affect binding at an SFPI1 (AKA PU.1) site at one of the three ZMIZ1 VDR peaks, and we had previously shown compelling evidence that this transcription factor interacts with VDR in MPs (7). GWAS risk SNPs affecting SFPI1 binding are typically this distance away from the SFPI1 recognition sequence (26) . This suggests the risk genotype association with expression and disease may be driven by SFPI1 and VDR in MP cells. Expression of ZMIZ1-AS1 is at a low level in all cells, but highest in mature DCs. Its expression was more dependent on risk genotype, and more responsive to vitamin D, than ZMIZ1. The role of this long non-coding RNA gene is unknown. Its expression was not correlated with that of ZMIZ1, and it has no homology with ZMIZ1 that would indicate complementary-nucleicacid-sequence-based regulation. If the risk SNP alters SFPI1 transcription, it is notable that there are two putative SFPI1 sites in ZMIZ1-AS1, such that local titration of binding by this transcription factor may be important. The high response of this gene to vitamin D, and especially of the protective allele, is consistent with a tolerogenic role. The SFPI1 gene encodes an E26 transformation-specific domain transcription factor that activates gene expression during myeloid and B-lymphoid cell development. The SFPI1 cistrome is associated with Alzheimer's disease, with higher expression of SFPI1 thought to tip the balance between neuroprotective and neurotoxic microglial function (27) .
The risk allele for IRF8 SNP rs13333054 is the same for MS and rheumatoid arthritis (investigated for the SNP rs13330176, which is in LD with rs13333054), but not yet examined for other LDADS. Intriguingly for the ZMIZ1 SNP rs1250551 the allelic association is reversed between MS and Crohn's disease, ankylosing spondylitis and inflammatory bowel disease; and not yet characterised for other LDADs. The increase in ZMIZ1 expression on stimulation with vitamin D was mainly allele independent, so consistent with higher expression in response to vitamin D being protective across the LDADs. However, the different allelic effects observed here in some contexts may have opposite consequences on the pathogenesis of each of the diseases, highlighting that the allelic and vitamin D effects on ZMIZ1 expression likely also depend on disease-specific immune contexts. The optimal therapeutic utility of vitamin D is therefore also likely to require more understanding of its role in pathogenesis for each disease, and the genetic associations should enable investigations to clarify this.
The stable relative set point for ZMIZ1 expression across DC types is consistent with the concept that homeostatic mechanisms may resist change in immune response; and may explain the observed reduced response to vitamin D for MS observed in some studies [25] . Doses and types of vitamin D used in therapy for autoimmune disease may need to be reconsidered if this is so.
The function of ZMIZ1-AS1 is unknown. The 'AS' of the name indicates it is encoded on the opposite strand to ZMIZ1 (28) . Because the MS risk genotype of this gene affects expression and response to vitamin D even more than these traits for ZMIZ1, ZMIZ1-AS1 function may be driving the association of the SNP with LDADs more than ZMIZ1. However, no protein has been identified for it, indicating it functions as a long noncoding RNA. Its expression level is very low compared to ZMIZ1, so that any effect is more likely to function at the DNA:DNA or mRNA:DNA level than the mRNA:mRNA level for example, switching expression away from ZMIZ1 at their joint promoter region. However, we found no evidence of complementary sequence between the ZMIZ1-AS1 gene and ZMIZ1 DNA, and the expression of the two genes was not negatively correlated. Some evidence of Fig. S1 ).
Risk genetic variants have their main functional effect in changing expression levels (29) . There are more risk genes with their highest expression in MP cells than T or B cells (30) , yet no therapy specifically targets this cell population. MP cells control the immune response by sensing pathogens and cell damage, secreting cytokines and presenting antigen to license T and B cells. Regulation of these processes is fundamental to avoiding autoimmunity. Of the MPs, DCs are predominantly located in lymphoid tissues, where they establish immune responses; and in tissues and circulating fluids, they respond to changes in cell state and infection. In the skin and draining lymph nodes they are directly responsive to sunlight induced vitamin D. This vitamin D can be locally produced 25D3 or 1,25D3 (31), available from 25D3 produced in the liver (catalysed by MS risk gene CYP2R1), or 1,25D3 produced in the kidneys (catalysed by MS risk gene CYP27B1). 25D3 can be converted to 1,25D3 in DCs by the MS risk gene CYP27B1. Of immune cells, DCs produce the highest amounts of CYP27B1, and also of the 1,25D3 inactivating enzyme, the MS risk genes CYP24A1 (15) . Risk genes for MS and other LDADs have an enrichment of VDR peaks in MPs compared to other diseases in the GWAS catalogue, including the pan LDAD risk genes ZMIZ1, ZMIZ1-AS1 and IRF8 (7); Fig. 1 ).
This study was conducted only on monocytes from healthy controls, on the assumption that the effect of disease susceptibility alleles would be detectable in the absence of disease. Monocytes and cells derived from those with MS may have altered epigenetic regulation, and response to vitamin D. Quite likely they have a reduced response, as has been detected in some studies (32) . This needs to be investigated as it affects the consequences of vitamin D supplementation. Many statistically significant findings were made in this study, indicating a relatively strong effect of the risk variants. However, larger cohorts and extended genotyping would enable better characterisation of the consequences of genetic variants in these immune contexts. Further, the systemic effects of changes in vitamin D treatment, or natural differences in 25D3 levels, would be affected by net changes in all immune cell types, and may be different from those identified here. Finally, monocytes from frozen cells, as used here, may have different responses to freshly derived monocytes.
Therefore, future work should test monocytes from people with LDADs, manipulation of peripheral blood mononuclear cells (PBMCs), rather than just monocytes and DCs, in vivo effects of vitamin D on these cell types due to risk genotype and the consequences of manipulating ZMIZ1, ZMIZ1-AS1, IRF8 and VDR activity on cell states, especially with nucleic acid therapeutics (33) .
In conclusion these data indicate vitamin D regulation of monocytes and DCs alters their phenotype to a more tolerogenic state through effects on expression of ZMIZ1, ZMIZ1-AS1 and IRF8, consistent with previous findings on risk gene effects seen for the vitamin D activation control genes CYP27B1 and CYP24A1, and supportive of this risk transcription factor network, VDR/ZMIZ1/IRF8, as suitable for manipulation in therapy. Following the massive global investment in gene discovery, this type of study contributes to the next phase of using knowledge of autoimmune disease genetic risk architecture to inform and drive novel studies of pathogenesis at a level of cellular and molecular detail sufficient to enable novel therapeutic intervention.
Materials and Methods
Isolation of monocytes from peripheral blood
PBMCs were isolated from buffy coat samples supplied by the Australian Red Cross Blood Donation Service using Ficoll Paque Plus (GE Healthcare, Chicago, IL). Isolated PBMCs were resus- pended into freezing medium (10% dimethyl sulfoxide (DMSO) in 50% fetal bovine serum in Roswell Park Memorial Institute (RPMI) 1640 medium) and temperature reduced to −80
• C using a CoolCell (Biocision, San Rafael, CA) and stored at −80 • C until monocyte isolation. Frozen cells were subsequently thawed and CD14+ monocytes were isolated using a Human CD14 Positive Selection Kit (Stem Cell Technologies, Canada) according to the manufacturer's instructions. Cell purification was determined by flow cytometry using antibodies detecting the cell surface markers CD14 and CD45.
Culture of monocyte-derived DCs
Isolated CD14+ monocytes were cultured in different conditions (as per 15) to generate monocyte-derived iDCs and tDCs, and to test the effect of culturing with vitamin D. In brief, cells were suspended in culture medium [X-Vivo15 (Lonza, Switzerland) containing 10 mm Hepes, 1% human AB serum, 2 mm Lglutamine 5 × 10 −5 M 2-mercaptoethanol] to a density of 2 × 10 6 per ml. Cultures were plated into 48-well plates using 250 μlitres of cell suspension per well and treated with three changes of granulocyte macrophage colony-stimulating factor (70 ng/ml) and IL-4 (10 ng/ml) over 4 days. On day 5, cells were treated with: lipopolysaccharide (250 ng/ml) only, to generate uDCs; lipopolysaccharide (250 ng/ml) and interferon-γ (10 ng/ml), to generate iDCs or lipopolysaccharide (250 ng/ml) and interferon-β (1000 IU/ml), to generate tDCs. Cells were cultured for 24 h with or without addition of calcipotriol (20 nM final concentration) and subsequently harvested into Cell-to-Signal Lysis Buffer (Thermo Fisher, Waltham, MA).
Isolation of RNA, cDNA Synthesis and gene expression assays
Total RNA was extracted from the harvested cells using an Isolate II RNA Micro Kit (Bioline, United Kingdom) and cDNA synthesised using the qScript cDNA supermix (Quanta Biosciences, Beverly, MA). Gene expression was determined by quantitative reverse transcription polymerase chain reaction (qRT-PCR) using TaqMan Universal Master Mix II and the following TaqMan gene expression assays (ZMIZ1: Hs01119362 m1, ZMIZ1-as1: Hs00404110 m1, IRF8: Hs00175238 m1, GAPDH: Hs02758991 g1, Life Technologies, Carlsbad, CA). Expression relative to the housekeeping gene, GAPDH, was calculated for each of the genes assayed.
Isolation of DNA from whole blood and genotyping of subjects
Genomic DNA was isolated from buffy coat aliquots for each of the subjects in the study using the Qiagen DNA Mini Kit (Qiagen, Germany) and genotyping assays were performed using the TaqMan Genotyping Mastermix (Thermo Fisher, Waltham, MA) to determine the genotype of the SNPs rs1250551 (ZMIZ1, ZMIZ1-AS1), rs13333054 (IRF8).
Statistical analysis
Data were analysed using GraphPad Prism 7 (GraphPad Software, La Jolla, CA) using two-tailed T-tests to compare between groups and Pearson's correlation to compare across genes. For some analyses, expression values were first converted to ranks, where each subject was ordered according their expression level for a given gene. This was done so the rank of a given subject could be compared across the different differentiation and treatment conditions assayed. Due to the expected independent effects of each of the genes measured and to minimise type two errors, no correction for multiple testing was performed on the P-values obtained in each of the tests.
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